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Background: Wilson disease (WD) is an autosomal recessive disorder. The WD gene, ATP7B, 
encodes a copper-transporting ATPase involved in the transport of copper into the plas-
ma protein ceruloplasmin and in excretion of copper from the liver. ATP7B mutations 
cause copper to accumulate in the liver and brain. 
Objectives: We examined the ATP7B mutation spectrum in Wilson disease patients in Iran.
Patients and Methods: Genomic DNA was extracted from patients with Wilson disease. The 
entire coding region of the ATP7B gene was ampliﬁed using PCR and analyzed using di-
rect sequencing.
Results: We identiﬁed ﬁve novel mutations in 5 Iranian patients with Wilson disease. The 
ﬁrst was a transversion, c.2363C > T, which led to an amino acid change from threonine to 
isoleucine. The second mutation was a deletion, c.2532delA (Val845Ser), which occurred 
in exon 10. The third mutation was a transition mutation, c.2311C > G (Leu770Leu), which 
occurred in the TM4 domain of the ATP7B protein. The fourth mutation was a transver-
sion, (c.3061G > A) (Lys1020Lys), in exon 14. Lastly, we identiﬁed a transversion, c.3206C 
> A (His1069Asn) in exon 14 which led to a change in function of the ATP loop domain of 
the ATP7B protein. The H1069Q mutation was identiﬁed as the most common mutation 
in our study population.
Conclusions: Based on our ﬁndings, the H1069Q may be a biomarker that can be used in a 
rapid detection assay for diagnosing WD patients.
 Implication for health policy/practice/research/medical education:
Although a variety of mutations have been identiﬁed in the ATP7 gene in Wilson disease patients around the world, there is not 
enough data about it in Iranian patients. This study will provide valuable information about mutational hot spot regions of ATP7B 
gene in Iranian patients for the ﬁrst time and may help researchers to develop speciﬁc diagnostic tests for our population. We 
highly recommend biologists and Gastroenterologists to study this article.
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1. Background
Wilson disease (WD, MIM #277900) is an autosomal re-
cessive disorder of copper metabolism resulting in toxic 
copper accumulation in the liver and other organs such 
as the brain, kidney, and cornea. Clinically, increased cop-
per in cells can result in hepatic cirrhosis and neurologi-
cal damage. The prevalence of WD varies from 1/30,000 
to 1/100,000 in diﬀerent populations, with an estimated 
carrier rate of 1 in 90 (1, 2). The WD gene, which maps to 
chromosome 13q14.3, encodes a 165 kDa copper-trans-
porting P-type ATPase, ATP7B (MIM #606882) (3). ATP7B 891 ATP7B Gene Mutations and Wilson Disease
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consists of 21 exons spanning a genomic region of ap-
proximately 80 kb. The protein is made up of 1465 amino 
acids and is predominantly expressed in the liver, with 
reduced expression in the brain, kidney, and placenta 
(4-6). ATP7B has several membrane-spanning domains, 
including 6 copper binding domains, 8 transmembrane 
domains (Tm), a transduction domain that uses energy 
from ATP hydrolysis for cation transport, a Tm cation 
domain, and a phosphorylation domain (7, 8). ATP7B mu-
tations result in copper accumulation in the liver and 
brain, resulting in clinical manifestations such as liver 
disease, hemolysis, renal alterations, and neuropsychiat-
ric disease. Kayser-Fleischer (KF) rings in the periphery of 
the cornea and copper abnormalities in serum and uri-
nary tests are frequently observed (9, 10). More than 270 
diﬀerent mutations have been identiﬁed in the ATP7B 
gene along the length of the coding region as well as in 
the promoter (11).
2. Objectives
The aim of this study was to identify mutations in a 
large group of Iranian patients with WD. This is the ﬁrst 
comprehensive mutation analysis of the Iranian popula-
tion.
3. Patients and Methods
A total of 70 WD patients, 40 males and 30 females, rang-
ing in age from 5–40 years from 54 families were includ-
ed in the study. Patients were diagnosed based on clinical 
symptoms. Hepatic patients showed liver involvement. 
Neurological patients showed neurological symptoms 
such as tremor, clumsiness, dysarthria, and ataxia in ad-
dition to Dystonic-Parkinsonian Syndrome. Mixed-type 
patients were diagnosed based on liver involvement and 
neurological features. Criteria for diagnosing patients 
with WD included serum ceruloplasmin levels of 20 mg/
dL, urine copper > 40 mmol/24 h, liver copper > 250 μg/g 
dry weight, and the presence of Kayser-Fleischer (K-F) 
rings. Patients who fulﬁlled 2 of these criteria were in-
cluded in the study. Patients who were positive for hepa-
titis C virus (HCV), hepatitis B surface antigen (HBsAg), or 
hepatitis B core antibody (HBCAb), or had acute hepatitis 
or malignant tumors were excluded. This investigation 
was approved by the local Research Center for Gastroen-
terology and Liver Diseases (RCGLD) ethics committee 
and appropriate informed consent was obtained from 
all patients and their families.
3.1. Polymerase Chain Reaction and Sequencing
DNA was extracted from whole blood using standard 
phenol-chloroform extraction (12) . ATP7B gene exons 
were ampliﬁed using PCR; 35 cycles, including a 30-s 
denaturing step at 94°C, a 30-s annealing step at the 
appropriate temperature, and a 35-s extension step at 
72°C, were used for ampliﬁcation. The reaction mixture 
contained 100 ng genomic DNA as the template, 19.4 μL 
dH2O, 0.5 μL 10 mM dNTP, 0.75 μL 50 mM MgCl2, 12.5 pM 
of each primer, and 1 unit of Taq DNA polymerase (Gibco 
BRL, Invitrogen, Carlsbad, CA, USA) in a total volume of 
25 μL. Primers were designed using Gene Runner and 
Primer3 software. Bi-directional PCR-sequencing was car-
ried out using the ABI 3130xl Genetic Analyzer (Applied-
Biosystems, Foster City, CA, USA). Sequences were aligned 
and analyzed using ClustalX2 and BioEdit software, 
respectively. To detect novel mutations and polymor-
phisms in the gene, 50 control samples were compared 
with samples from diseased patients. Changes were 
classiﬁed as polymorphisms if they did not change the 
amino acid sequence or when they were also detected in 
normal chromosomes. Based on mutations recorded at 
http://www.HGMD.org/, the detected mutations were 
named using the sequence with the GenBank accession 
number NM_00053.1 as a reference. 
4. Results
The clinical characteristics of 70 patients with WD 
were evaluated. Of the 70 patients, 21 (22.8%) had at least 
1 mutation. Among the 21 patients with mutations, age 
at diagnosis ranged from 7 to 25 years (Table 1). A total 
of 21 diﬀerent mutations were identiﬁed. According to 
recent publications and the “Wilson disease mutation 
database” (http://www.uofa-medical-genetics.org/
wilson/index.html), we identiﬁed 5 novel mutations 
that aﬀect various protein domains of the ATP7B gene; 
Figure 1. Sequencing Result for ﬁve Novel Mutations: A) c.3061G > A 
(K1020K) in exon 14, B) c.2363C > T (T787I) in exon 9, C) c.2532delA in 
exon10, D) c.3206C > A (H1069N) in exon 14 , E) c2311C > G(L770L) in exon 8892 ATP7B Gene Mutations and Wilson Disease Zali N et al.
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Patient ID Age at Onset of Symptoms Sex Hepatic Failure Neurological Manifestation KFR a
869710 23 Female + _ +
869711 28 Female _ + +
869171 9 Female + _ +
869911 22 Male + + +
869176 14 Male + + +
869346 21 Female + + +
Table 3. Clinical Features of Individuals With Novel Mutations
a Abbreviation: KFR, kayser-ﬂeisher ring
Mutation Nucleotide Change Type Exon Domain Manifestation KF a Ring 
(+/-)
Age at Onset of 
Symptoms
G85V 254G > T Missense 2 Cu1 (CuBD) H a _1 0
845delT 845delT Deletion 2 CuBD H + 7
1639delAT 1639delAT Deletion 6 Between CuBD and TM H + 9
D642H 1924G > C Missense 6 Cu6/TM1 H/N a _1 6
P840L 2519C > T Missense 10 TD H _ 25
V890M 2668G > A Missense 11 TD/TM5 H _ 19
H1069Q 3207C > A Missense 14 ATP loop 4
A874V 2621C > T Missense 11 TD H _ 12
A874V 2621C > T Missense 11 TD H _ 14
H1069Q 3207C > A Missense 14 ATP loop H + 17
H1069Q 3207C > A Missense 14 ATP loop H + 18
H1069Q 3207C > A Missense 14 ATP loop H + 18
L1120X 3359T > A Nonsense 15 ATP loop H + 11
N1270S 3809A > G Missense 18 ATP hinge H/N + 17
N1270S 3809A > G Missense 18 ATP hinge N _ 17
R778L 2333G > T Missense 8 TM4 H + 22
R969Q 2906G > A Missense 13 TM6 H + 22
Table 1. Characteristics of Mutations and Individual Phenotype
a Abbreviations: H, hepatic symptom: kayser-ﬂeisher N, neurologic symptom; KF
Patient ID Nucleotide Accession No. Nucleotide Change a Type Exon Aﬀected Protein Domain
869710, 869711 c.2363C > T EU041762 p.Thr787Ile Missense 9 TM4
869171 c.2532delA EF643605 p.Val845Ser Deletion 10 TD
869911 c.2311C > G EF643606 p.Leu770Leu Silent 8 TM4
869176 c.3061G > A EF643604 p.Lys1020Lys Silent 14 ATP loop
869346 c.3206C > A EF620914 p.His1069Asn Missense 14 ATP loop
 Table 2. Characteristics of 5 Novel Mutations 
a Numbering based on cDNA sequence, position +1 corresponds to the A of the ATG translation initiation codon in reference sequence; ATP7B [GenBank: 
NM 00053.1]
these mutations include c.2363C > T, c.2532delA, c.2311C > 
G, c.3061G > A, and c.3206C > A (Table 2, Figure 1). 
Table 3 shows that a novel substitution in exon 9 involv-
ing the protein transmembrane domain at Thr787Ile 
was identiﬁed in 2 homozygous patients who were 23- 
and 28-year-old sisters; interestingly, the older sister (28 
years) exhibited only neurologic manifestations, while 
the younger (23 years) presented with acute hepatic 
failure and had undergone liver transplantation. Both 
exhibited the KF ring. The second novel mutation identi-
ﬁed in this study was a deletion in exon 10 (c.2532delA) in 
a 9-year old girl presenting with hepatic failure and neu-
rological features. She also showed the KF ring. The third 
novel mutation, 2311C > G, was identiﬁed in a 22-year-
old man, who demonstrated hepatic and neurologic 
features accompanied by the KF ring. The fourth novel 
mutation, c.3061G > A, was a silent mutation identiﬁed 
in exon 14. This mutation was found in a 14-year-old boy 893 ATP7B Gene Mutations and Wilson Disease
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who also exhibited the KF ring. The ﬁfth novel mutation, 
c.3206C > A, was detected in a hot spot region of exon 14. 
It was detected in a 21-year old girl presenting with acute 
hepatic failure and neurological manifestations. Addi-
tionally, she exhibited the KF ring. A total of 20 (28.6%) 
patients with mutations were homozygous, while one 
patient (1.4%) had a compound heterozygous mutation. 
The most commonly observed mutation was the H1069Q 
point mutation in 4 of 21 patients (19%), all of whom were 
homozygous. Interestingly, the D642H mutation was de-
tected in members of the same family. This mutation re-
sulted in both hepatic and neurological symptoms. Two 
sisters with hepatic WD were heterozygous for this mu-
tation, while their brother was homozygous for D642H. 
He exhibited neurological symptoms of WD. Thus, the 
D642H mutation has been detected in one family and ex-
hibited both hepatic and mixed WD presentations. 
Table 2 summarizes the mutations identiﬁed and corre-
sponding ages at disease onset, presence of the KF ring, 
and involvement of the liver, brain, or both. In addition 
to the 21 diﬀerent mutations, 6 diﬀerent sequence varia-
tions with no clinical signiﬁcance were identiﬁed (Table 
4). These variants were identiﬁed in previous studies as 
polymorphisms detected in a normal population or as 
those not altering amino acid composition of the pro-
tein. To clarify whether these nucleotide and amino acid 
sequence changes were mutations or polymorphisms, 
we analyzed 50 normal individuals using direct sequenc-
ing of their PCR products.
5. Discussion 
In this study, we examined the mutation spectrum 
of the ATP7B gene among the Iranian population. We 
identiﬁed 21 diﬀerent mutations, including 5 novel, dis-
ease-causing mutations in 21 individuals in 70 referred 
patients, reﬂecting the genetic heterogeneity of Wilson 
disease. Population-frequency values of these mutations 
revealed that the spectrum of WD mutations consists of 
a large number of rare mutations. Six single nucleotide 
polymorphisms (SNPs) were identiﬁed (Table 4). An inter-
esting case of marked clinical heterogeneity within a sin-
gle family included 2 sisters with the homozygous T787I 
mutation. One exhibited only neurological manifesta-
tions, while the other presented with acute hepatic fail-
ure and had undergone liver transplantation. This con-
siderable phenotypic variation for the same genotype 
suggests involvement of additional genetic, epigenetic, 
or even environmental factors in the pathogenesis of 
Wilson disease. The pathogenicity of the novel missense 
mutation T787I was evaluated for 3 primary factors. First, 
segregation analysis was performed using variable SNPs 
within the ATP7B gene in this family, which conﬁrmed 
the presence of a mutation in the ATP7B gene responsible 
for causing WD. Second, T787I was not detected among 
50 unrelated control subjects screened. Third, a muta-
tion is presumed to be pathologic when it is located in 
the conserved region of a gene. However, the change in 
a hydrophilic amino acid, threonine, to a non-polar hy-
drophobic amino acid, isoleucine, in a conserved trans-
membrane domain of a protein can change its function. 
Further investigation is necessary to elucidate the details 
of this abnormal function. The most frequently observed 
mutation in the ATP7B gene responsible for causing WD 
in the U.S. and in central Europe is H1069Q, which is lo-
cated in exon 14. For instance, this mutation occurs at 
frequencies of 61% among Austrian, 39% among Russian, 
38% among North American and Swedish, 34% among 
Dutch, 28% among Canadian, 17% among Turkish, and 12% 
among Italian Wilson patients. It is associated with CNS 
diseases and a later onset of disease (5, 13, 14). However, 
we observed this mutation in four (19%) patients, all of 
whom had only hepatic symptoms and were 5–40 years 
of age. This mutation disrupts the unique SEHPL amino 
acid motif and leads to a deﬁciency in ATP binding (6). 
The 5 novel mutations included missense, silent, and de-
letion mutations. One was a novel causative mutation, 
H1069N. We screened 50 unrelated individuals for this 
mutation; none of the tested subjects was a heterozygote 
or a homozygote. The H1069N mutation occurs in a con-
served region, and involves the conversion of the non-
polar amino acid histidine to the hydrophilic amino acid 
asparagine within the highly-conserved SEHPL domain; 
alterations in this region are highly deleterious (15, 16). 
The Thr787Ile substitution replaces a polar residue with a 
non-polar and hydrophobic amino acid. This mutation is 
expected to change the function of the transmembrane 
domain by altering secondary structure. The c.2532delA 
is a deletion of a nucleotide (A) in exon 10; however, this 
mutation is silent.
Mutations 2311C > G and 3060G > A were also silent; 
thus, no alteration in amino acid sequence was observed. 
R778L is one of the most prevalent mutations in Eastern 
Asian patients and leads to liver involvement in WD pa-
tients (17-20) .We observed this mutation in a compound 
heterozygous state with R969Q in 1 patient with hepatic 
SNP Exon Frequency in Cases Frequency in Controls
T1216G (A405S) 2 0.30 0.32
G1367C (L456V) 3 0.23 0.35
A2495G (K831R) 10 0.31 0.38
G2855A (K952R) 12 0.26 0.31
G3009A (A1003A) 13 0.1 0.15
G2973A (T991T) 13 0.05 0.08
Table 4. Comparison of Observed Polymorphisms in WD Patients and Control Patients894 ATP7B Gene Mutations and Wilson Disease Zali N et al.
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failure. This ﬁnding may be related to the mixed ethnic 
background of the Iranian population. H1069Q is the 
most commonly observed mutation responsible for WD 
in our patients. This ﬁnding highlights the importance 
of ATP7B mutation screening in high-risk consanguine-
ous marriages. The signiﬁcance of the various mutations 
remains to be elucidated, and we could not identify clear 
genotype-phenotype associations; thus, further stud-
ies are needed. In conclusion, although mutations were 
distributed among diﬀerent exons of the ATP7B gene in 
Iranian patients with WD, 6 of 21 mutations were located 
in exon 14. Therefore, this exon may be a mutational hot 
spot in the Iranian population. This ﬁnding is compat-
ible with the results from Western countries and in con-
trast with results from China. Hot spot exons reported 
in Western countries were 14 and 18, while the hot spot 
exons reported in China were 8 and 12 (20). These results 
are important for establishing a rapid and accurate mu-
tation analysis method for diagnosing WD patients in 
the Iranian population.
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